These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11165816)

  • 1. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems.
    Kranz H; Brazeau GA; Napaporn J; Martin RL; Millard W; Bodmeier R
    Int J Pharm; 2001 Jan; 212(1):11-8. PubMed ID: 11165816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myotoxicity studies of O/W-in situ forming microparticle systems.
    Rungseevijitprapa W; Brazeau GA; Simkins JW; Bodmeier R
    Eur J Pharm Biopharm; 2008 May; 69(1):126-33. PubMed ID: 18036794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
    Kranz H; Bodmeier R
    Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
    Kranz H; Bodmeier R
    Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo drug release from a novel in situ forming drug delivery system.
    Kranz H; Yilmaz E; Brazeau GA; Bodmeier R
    Pharm Res; 2008 Jun; 25(6):1347-54. PubMed ID: 17968634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability.
    Ahmed TA; Ibrahim HM; Samy AM; Kaseem A; Nutan MT; Hussain MD
    AAPS PharmSciTech; 2014 Jun; 15(3):772-80. PubMed ID: 24648158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of PLGA microsphere size effect on myotoxicity using the isolated rodent skeletal muscle model.
    Brazeau GA; Sciame M; al-Suwayeh SA; Fattal E
    Pharm Dev Technol; 1996 Oct; 1(3):279-83. PubMed ID: 9552310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.
    Ahmed TA; Ibrahim HM; Ibrahim F; Samy AM; Kaseem A; Nutan MT; Hussain MD
    J Pharm Sci; 2012 Oct; 101(10):3753-62. PubMed ID: 22753324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro-in vivo myotoxicity of intramuscular liposomal formulations.
    al-Suwayeh SA; Tebbett IR; Wielbo D; Brazeau GA
    Pharm Res; 1996 Sep; 13(9):1384-8. PubMed ID: 8893279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
    Luan X; Bodmeier R
    J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the myotoxicity of pharmaceutical buffers using an in vitro muscle model: effect of pH, capacity, tonicity, and buffer type.
    Napaporn J; Thomas M; Svetic KA; Shahrokh Z; Brazeau GA
    Pharm Dev Technol; 2000; 5(1):123-30. PubMed ID: 10669926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.
    Dong WY; Körber M; López Esguerra V; Bodmeier R
    J Control Release; 2006 Oct; 115(2):158-67. PubMed ID: 16963145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery.
    Brazeau GA; Attia S; Poxon S; Hughes JA
    Pharm Res; 1998 May; 15(5):680-4. PubMed ID: 9619774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery.
    Yehia SA; Elshafeey AH; Elsayed I
    J Liposome Res; 2012 Jun; 22(2):128-38. PubMed ID: 22091557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers.
    Chandrashekar G; Udupa N
    J Pharm Pharmacol; 1996 Jul; 48(7):669-74. PubMed ID: 8866326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ gel formulations for gene delivery: release and myotoxicity studies.
    Ismail FA; Napaporn J; Hughes JA; Brazeau GA
    Pharm Dev Technol; 2000; 5(3):391-7. PubMed ID: 10934739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ micro-sized gel-forming injectable implant using biodegradable amphiphilic graft copolymer.
    Cho KY; Lee S; Park JK
    Macromol Biosci; 2007 Jun; 7(6):784-8. PubMed ID: 17541923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of particle size of parenteral suspensions on in vitro muscle damage.
    Brazeau G; Sauberan SL; Gatlin L; Wisniecki P; Shah J
    Pharm Dev Technol; 2011; 16(6):591-8. PubMed ID: 21214423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biocompatibility of lipid-protein-sugar particles containing bupivacaine in the epineurium.
    Kohane DS; Lipp M; Kinney RC; Anthony DC; Louis DN; Lotan N; Langer R
    J Biomed Mater Res; 2002 Mar; 59(3):450-9. PubMed ID: 11774302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro and In Vivo Evaluation of Lidocaine Hydrochloride-loaded Injectable Poly(Lactic-co-glycolic Acid) Implants.
    Li Y; Shi X
    Curr Drug Deliv; 2018; 15(10):1411-1416. PubMed ID: 30207229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.